TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RedHill Biopharma ( (RDHL) ) has issued an update.
On August 18, 2025, RedHill Biopharma announced it received its first milestone payment of $1.1 million for Talicia’s sales outside the U.S. following its commercial launch in 2024. Talicia, a leading therapy for H. pylori infection, addresses the high resistance rates of the bacteria to other antibiotics, offering a significant advancement in treatment. This milestone highlights RedHill’s strategic expansion and potential for additional revenue streams through global partnerships, reinforcing its position in the pharmaceutical industry.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
The most significant risk comes from financial performance, with negative margins and cash flow problems posing major challenges. Technical analysis supports a bearish trend. Lack of valuation data and earnings call information limits further insights.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary drugs for the treatment of gastrointestinal and infectious diseases. The company is known for its product Talicia, which is the first FDA-approved rifabutin-based therapy specifically designed to treat Helicobacter pylori infections.
Average Trading Volume: 478,935
Technical Sentiment Signal: Sell
Current Market Cap: $3.12M
See more data about RDHL stock on TipRanks’ Stock Analysis page.